ITEM 2
– MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Caution Regarding Forward-Looking Information
In addition to historical information, this Form 10-Q
contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA.
All statements contained in this Form 10-Q, other than statements of historical facts, that address future activities, events or developments are forward-looking statements, including, but not limited to, statements containing the words “believe,” “expect,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new products, services, developments or industry rankings; any statements regarding future revenue, economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. These statements are based on certain assumptions and analyses made by us in light of our experience and our assessment of historical trends, current conditions and expected future developments as well as other factors we believe are appropriate under the circumstances. However, whether actual results will conform to the expectations and predictions of management is subject to a number of risks and uncertainties described under Item 1A - Risk Factors beginning on page 18 below that may cause actual results to differ materially.
Consequently, all of the forward-looking statements made in this Form 10-Q
are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by management will be realized or, even if substantially realized, that they will have the expected consequences to or effects on our business operations. Readers are cautioned not to place undue reliance on such forward-looking statements as they speak only of the Company’s views as of the date the statement was made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Critical Accounting Policies and Estimates
The discussion and analysis of the Company
’s financial condition and results of operations are based upon its consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent liabilities. On an on-going basis, management evaluates past judgments and estimates, including those related to bad debts, inventories, accrued liabilities, derivative liabilities and contingencies. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The accounting policies and related risks described in the Company’s annual report on Form 10-K as filed with the SEC on September 28, 2017 are those that depend most heavily on these judgments and estimates. As of December 31, 2017 there had been no material changes to any of the critical accounting policies contained therein.
Overview
IsoRay, Inc. is a brachytherapy device manufacturer with FDA clearance and CE marking for a single medical device that can be delivered to the physician in multiple configurations as pr
escribed for the treatment of cancers in multiple body sites. The Company manufactures and sells this product as the Cesium-131 brachytherapy seed.
The brachytherapy seed utilizes Cesium-131, with a 9.7 day half-life, as its radiation source. The Company
believes that it is the unique combination of the short half-life and the energy of the Cesium-131 isotope that are yielding the beneficial treatment results that have been published in peer reviewed journal articles and presented in various forms at conferences and tradeshows.
The Company has distribution agreements outside of the United States through its subsidiary IsoRay International LLC. These distributors are responsible for obtaining regulatory clearance to sell the Company
’s products in their territories, with the support of the Company. As of the date of this Report, the Company had distributors in Italy and the Russian Federation
.
Results of Operations
Three months
ended
December 31
,
2017
and
2016
(in thousands)
:
|
|
Three months
ended December 31,
|
|
|
|
2017
|
|
|
2016
|
|
|
2017 - 2016
|
|
|
|
Amount
|
|
|
% (a)
|
|
|
Amount
|
|
|
% (a)
|
|
|
% Change
|
|
Product sales, net
|
|
$
|
1,536
|
|
|
|
100
|
|
|
$
|
1,028
|
|
|
|
100
|
|
|
|
49
|
|
Cost of product sales
|
|
|
1,005
|
|
|
|
65
|
|
|
|
1,029
|
|
|
|
100
|
|
|
|
(2
|
)
|
Gross profit
/ (loss)
|
|
|
531
|
|
|
|
35
|
|
|
|
(1
|
)
|
|
|
-
|
|
|
|
53,200
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses - proprietary
|
|
|
311
|
|
|
|
20
|
|
|
|
150
|
|
|
|
15
|
|
|
|
107
|
|
Research and development expenses
– collaboration agreement, net of reimbursement
|
|
|
29
|
|
|
|
2
|
|
|
|
-
|
|
|
|
-
|
|
|
|
100
|
|
Sales and marketing expenses
|
|
|
674
|
|
|
|
44
|
|
|
|
496
|
|
|
|
48
|
|
|
|
35
|
|
General and administrative expenses
|
|
|
985
|
|
|
|
64
|
|
|
|
880
|
|
|
|
86
|
|
|
|
12
|
|
Change in estimate of ARO
|
|
|
-
|
|
|
|
-
|
|
|
|
(48
|
)
|
|
|
(5
|
)
|
|
|
(100
|
)
|
Total operating expenses
|
|
|
1,999
|
|
|
|
130
|
|
|
|
1,478
|
|
|
|
144
|
|
|
|
35
|
|
Operating loss
|
|
|
(1,468
|
)
|
|
|
(95
|
)
|
|
|
(1,479
|
)
|
|
|
(144
|
)
|
|
|
1
|
|
|
(a)
|
Expressed as a percentage of product sales, net
|
Six months ended December 31,
2017
and
2016
(in thousands)
:
|
|
Six months ended December 31,
|
|
|
|
2017
|
|
|
2016
|
|
|
2017 - 2016
|
|
|
|
Amount
|
|
|
% (a)
|
|
|
Amount
|
|
|
% (a)
|
|
|
% Change
|
|
Product sales, net
|
|
$
|
2,747
|
|
|
|
100
|
|
|
$
|
2,109
|
|
|
|
100
|
|
|
|
30
|
|
Cost of product sales
|
|
|
1,951
|
|
|
|
71
|
|
|
|
2,062
|
|
|
|
98
|
|
|
|
(5
|
)
|
Gross profit / (loss)
|
|
|
796
|
|
|
|
29
|
|
|
|
47
|
|
|
|
2
|
|
|
|
1,594
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses
- proprietary
|
|
|
597
|
|
|
|
22
|
|
|
|
322
|
|
|
|
15
|
|
|
|
85
|
|
Research and development expenses
– collaboration agreement, net of reimbursement
|
|
|
104
|
|
|
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales and marketing expenses
|
|
|
1,288
|
|
|
|
47
|
|
|
|
1,020
|
|
|
|
48
|
|
|
|
26
|
|
General and administrative expenses
|
|
|
1,827
|
|
|
|
67
|
|
|
|
1,807
|
|
|
|
86
|
|
|
|
(1
|
)
|
Change in estimate of ARO
|
|
|
-
|
|
|
|
-
|
|
|
|
(48
|
)
|
|
|
(2
|
)
|
|
|
(100
|
)
|
Total operating expenses
|
|
|
3,816
|
|
|
|
140
|
|
|
|
3,101
|
|
|
|
147
|
|
|
|
23
|
|
Operating loss
|
|
|
(3,020
|
)
|
|
|
(111
|
)
|
|
|
(3,054
|
)
|
|
|
(145
|
)
|
|
|
1
|
|
|
(a)
|
Expressed as a percentage of product sales, net
|
Product Sales
Changes in sales personnel and implementation of
a revitalized sales and marketing strategy in the second quarter of fiscal 2017 has resulted in positive sales growth in the second quarter of fiscal 2018 when compared to prior year second quarter. Ongoing training and support of new sales personnel has led to not only new accounts but also reconnecting with and receiving orders from prior accounts.
Three months ended December 31,
2017
and
2016
(in thousands)
|
|
Three months
ended December 31,
|
|
|
|
2017
|
|
|
2016
|
|
|
2017 - 2016
|
|
|
|
Amount
|
|
|
% (a)
|
|
|
Amount
|
|
|
% (a)
|
|
|
% Change
|
|
Prostate brachytherapy
|
|
$
|
1,315
|
|
|
|
86
|
|
|
$
|
889
|
|
|
|
86
|
|
|
|
48
|
|
Other brachytherapy
|
|
|
221
|
|
|
|
14
|
|
|
|
139
|
|
|
|
14
|
|
|
|
59
|
|
Product sales, net
|
|
|
1,536
|
|
|
|
100
|
|
|
|
1,028
|
|
|
|
100
|
|
|
|
49
|
|
|
(a)
|
Expressed as a percentage of product sales, net
|
Six months ended December 31,
2017
and
2016
(in thousands)
|
|
Six months ended December 31,
|
|
|
|
201
7
|
|
|
201
6
|
|
|
201
7 - 2016
|
|
|
|
Amount
|
|
|
% (a)
|
|
|
Amount
|
|
|
% (a)
|
|
|
% Change
|
|
Prostate brachytherapy
|
|
$
|
2,399
|
|
|
|
87
|
|
|
$
|
1,855
|
|
|
|
88
|
|
|
|
29
|
|
Other brachytherapy
|
|
|
348
|
|
|
|
13
|
|
|
|
254
|
|
|
|
12
|
|
|
|
37
|
|
Product sales, net
|
|
|
2,747
|
|
|
|
100
|
|
|
|
2,109
|
|
|
|
100
|
|
|
|
30
|
|
|
(a)
|
Expressed as a percentage of product sales, net
|
Prostate Brachytherapy
During the quarter ended December 31, 2017, the Company had a full sales team in place contributing to the increase in sales. Also, website improvements and significant investments in product support literature, social media and public relations are increasing the awareness of the Company in the prostate brachytherapy treatment markets providing the Company opportunities to develop new customers and reconnect with past customers.
Management believes growth in prostate brachytherapy revenues will be the result of physicians, payers, and patients increasingly considering overall brachytherapy treat
ment advantages including costs, better treatment outcomes and improvement in the quality of life for patients, when compared with non-brachytherapy treatments.
During the quarter ended December 31, 2017, approximately $35,000 of reported revenues originated from the international market.
Management believes increased pressure to deliver effective healthcare in both terms of outco
me and cost drove treatment options, and accordingly drove the Company’s prostate revenues, in the quarter ended December 31, 2017.
Other Brachyth
erapy
Other brachytherapy includes, but is not limited to, brain, lung, head/neck, and gynecological treatm
ents. Initial applications for these other brachytherapy treatments are primarily used in recurrent cancer treatments or salvage cases that are generally difficult to treat aggressive cancers where other treatment options are either ineffective or unavailable.
These other brachytherapy treatments continue to be subject to the influence of a small pool of innovative physicians who are the early adopters of the technology who also tend to be faculty at teaching hospitals training the next generation of phys
icians. This causes the revenue created by these types of treatment applications to be more volatile and vary significantly from quarter to quarter. This volatility resulted in the increase from the prior year.
Cost of product sales
Cost of product sales
consists primarily of the costs of manufacturing and distributing the Company’s products.
Contributing to the
three and six months ended December 31, 2017 and 2016 comparison were decreases attributed to cost savings initiatives that resulted in lower procurement costs of goods and services. Some costs shifted in the three and six months ended December 31, 2017 to research and development from cost of product sales as employees performed research and development work. Also, reduced staffing costs were realized with decreased head count. These decreases were partially offset by increased supply of isotope from MURR which increased total cost of product sales but resulted in lower supply cost per curie of Cesium-131.
Res
earch and development
Research and development
– proprietary
Proprietary research and development consists primarily of employee and third-party costs related to research and development activities.
Contributing to the
three months ended December 31, 2017 and 2016 proprietary research and development comparison were increases associated with participation in new protocols, device development activities, as well as a reallocation of employee costs from cost of product sales as those employees performed work on research and development projects.
Contributing to the
six months ended December 31, 2017 and 2016 proprietary research and development comparison were increases associated with participation in new protocols, device development activities, as well as a reallocation of employee costs from cost of product sales as those employees performed work on research and development projects. These increases were partially offset by decreased legal fees.
Research and development
– collaborative arrangement
Collaboration arrangement related costs are incurred, shared, and separately stated in connection with a collaborative research and development project with GammaTile, LLC.
During the three months ended December
31, 2017 and 2016, costs incurred in connection with the collaboration agreement were $58,000 and $0, respectively.
During the six months ended December 31, 2017 and 2016, costs incurred in connection with the collaboration agreement were $205,000 and $0
, respectively.
Sales and marketing expenses
Sales and marketing expenses consist primarily of the costs related to the internal and external activities of the Company
’s sales, marketing and customer service functions of the Company. As the Company increasingly focuses on improving sales, the cost associated with marketing and greater staffing continues to increase.
S
taffing differences are a major factor in the cost comparison for the three months ended December 31, 2017 and 2016 as open positions in the quarter ended December 31, 2016 were filled in periods prior to the quarter ended December 31, 2017 with increased salaries and increased travel costs
. Due to increased sales, there were also increases in commission and bonus expense.
Contributing to the six months ended December 31, 2017 and 2016 comparison were increased advertising and public relations costs as part of the revitalized marketing plan. Staffing differences are a major factor in the cost comparison as open positi
ons in six months ended December 31, 2016 were filled in periods prior to the quarter ended December 31, 2017 with increased salaries.
Gene
ral and administrative expenses
General and administrative expenses consist pri
marily of the costs related to the executive, human resources/training quality assurance/regulatory affairs, finance, and information technology functions of the Company.
Contributing to the
three months ended December 31, 2017 and 2016 comparison were cost increases associated with share-based compensation, bonus expense, public company related expense, and state tax expense. These cost increases were partially offset in the three months ended December 31, 2017 by decreases to payroll as a result of the re-organization of the finance department with reduced head count, decreased legal expenses, and decreased employee hiring costs.
Contributing to the
six months ended December 31, 2017 and 2016 comparison were cost decreases from the prior year. Those include decreases to payroll as a result of the re-organization of the finance department with reduced head count, decreased legal expenses, audit and bank fees, and seminars, conference, and training expenses. These cost decreases were partially offset in the six months ended December 31, 2017 by increases associated with share-based compensation, bonus expense, state taxes, and employment hiring expenses related to the hiring of the Controller.
Liquidity and capital
resources
The Company assesses its liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. The Company has historically financed its operations through selling equity to investors. During the quarter
s ended December 31, 2017 and 2016, the Company used existing cash reserves to fund its operations and capital expenditures (in thousands except current ratio):
|
|
Six months
|
|
|
|
ended
December 31,
|
|
|
|
2017
|
|
|
2016
|
|
Net cash used by operating activities
|
|
$
|
(3,184
|
)
|
|
$
|
(3,014
|
)
|
Net cash
provided by investing activities
|
|
|
164
|
|
|
|
(448
|
)
|
Net cash provided by financing activities
|
|
|
39
|
|
|
|
(9
|
)
|
Net decreases in cash and cash equivalents
|
|
$
|
(2,981
|
)
|
|
$
|
(3,471
|
)
|
|
|
As of
|
|
|
|
December 31, 2017
|
|
|
June 30, 2017
|
|
Working capital
|
|
$
|
6,486
|
|
|
$
|
9,185
|
|
Current ratio
|
|
|
7.96
|
|
|
|
9.30
|
|
Cash flows from operating activities
Net cash used by operating activities in the
six months ended December 31, 2017 was primarily due to a net loss of approximately $3.01 million
, net of approximately $317,000 in adjustments for non-cash activity such as depreciation and amortization expense, ARO accretion, and share-based compensation. Changes in operating assets and liabilities used approximately $491,000 to fund operating activities; Increase in accounts receivable and inventory, along with decreases in accounts payable and accrued expenses were partially offset by an increase in accrued payroll and related taxes.
Cash flows from
investing activities
Investing activities consisted of transactions related to the purchase of fixed assets, including automation
of production processes and advance planning and design work on the Company’s new production facility, as well as the purchase and subsequent maturity of certificates of deposit. Management will continue to invest in technology and machinery that improves and streamlines production processes and to invest maturing certificates of deposit in low-risk investment opportunities that safeguard assets and provide greater assurance those resources will be liquid and available for business needs as they arise.
Cash flows from financing activities
Financing activities in the
six months ended December 31, 2017 included payment of preferred dividends and proceeds of sales of common stock through option exercises.
Projected
2018
Liquidity and Capital Resources
Operating activities
Management forecasts that current cash and cash equivalents along with certificates of deposit will be
sufficient to meet projected operating cash needs for the remainder of fiscal 2018 and into the first half of fiscal 2019. Assuming no extraordinary expenses occur (whether operating or capital), if management is successful at implementing its strategy of renewed emphasis on driving the consumer to the prostate market, meets or exceeds its annual growth targets of twenty percent increase in revenue in fiscal 2018 and this annual growth continues, the Company anticipates reaching cashflow break-even in three to five years. Although the Company did not reach that target of twenty percent increased revenue in the first quarter of fiscal 2018, that target was surpassed in the second quarter and the Company is continuing to project revenue growth in fiscal 2018 of at least twenty percent over fiscal 2017. There is no assurance that targeted sales growth will materialize over the next three to five years. However, management is encouraged by the results for the six months ended December 31, 2017 and with the depth and experience of its restructured sales team.
Capital expenditures
Management has completed the design of a future production and administration facility. If financing is obtained a
nd the facility constructed, it is believed that the new facility will have non-cash depreciation cost equal to or greater than the monthly rental cost of the current facility.
Management is reviewing and implementing changes in all aspects of production
operations (including process automation), research and development, sales and marketing, and general and administrative functions to evaluate the most efficient deployment of capital to ensure that the appropriate materials, systems, and personnel are available to support and drive product sales.
During the six month
s ended December 31, 2017, the Company invested approximately $112,000 in the automation of production processes, three of which have been received, tested and evaluated, and were placed in service in the six months. One additional machine has been received and is currently being tested. Beginning in fiscal 2017 and continuing through December 31, 2017, the Company has invested approximately $412,000 in these automation projects and management is expecting to invest approximately $400,000 more over the next 18 months on the remaining projects. This investment is designed to allow the Company to significantly increase the output of Cs-131 brachytherapy seeds, while allowing the Company to decrease the labor costs related to seed production and also improving the overall safety of our operations.
Financing activities
There was no material change in the use of proceeds from our public offering as described in our final prospectus
supplement filed with the SEC pursuant to Rule 424(b) on March 24, 2014. Through December 31, 2017, the Company had used the net proceeds raised through the March 2014 offering as described in the public offering. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.
On August 25, 2015, the Company filed a registration statement on Form S-3 to register securities up to $20 million in value for future issuance in our capital raising activities. The registration statement became effectiv
e on November 19, 2015, and the SEC file number assigned to the registration statement is 333-206559.
The Company expects to finance its future cash needs through sales of equity, possible strategic collaborations, debt financing or through other sources
that may be dilutive to existing shareholders. Management anticipates that if it raises additional financing that it will be at a discount to the market price and it will be dilutive to shareholders.
The Company
’s common stock is currently listed on the NYSE American stock exchange, which will consider delisting a company’s securities if, among other things, a company fails to maintain minimum stockholder's equity. With the Company’s existing cash reserves, we believe we will not be able to maintain our listing on the NYSE American unless we raise capital in the next three to six months assuming we maintain our projected budgeted expenses and contemplated level of revenues.
Other Commitments and Contingencies
The Company presented its other commitment
s and contingencies in our Annual Report on Form 10-K for the fiscal year ended June 30, 2017. There have been no material changes outside of the ordinary course of business in those obligations during the quarter ended December 31, 2017 other than those previously disclosed in Notes 8 and 13 to the interim financial statements contained in this Form 10-Q.
Off-Balance Sheet Arrangements
The Company has no off-balance sheet arrangements.
Critical Accounting Policies and Estimates
T
he discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of these consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as revenue and expenses during the reporting periods. The Company evaluates its estimates and judgments on an ongoing basis. The Company bases its estimates on historical experience and on various other factors the Company believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities. Actual results could therefore differ materially from those estimates if actual conditions differ from our assumptions.
During the quarter ended
December 31, 2017, there have been no changes to the critical accounting policies and estimates, as discussed in Part II, Item 7 of our Form 10-K for the year ended June 30, 2017
.